Can biktarvy help Late-Stage HIV patients catch up?
NCT ID NCT04296695
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 4 trial tested the HIV drug Biktarvy in 202 people who were newly diagnosed with HIV and had low CD4 counts (under 200), meaning they started treatment late. Participants received either Biktarvy or a standard three-drug combination. The main goal was to see how many had undetectable virus levels at 12 weeks, with additional checks at 4, 24, and 48 weeks. The study also tracked changes in immune cell counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- What this could lead to
- If successful, this could show that Biktarvy is a safe and effective option for people who start HIV treatment late, helping them achieve viral suppression and immune recovery.
- What could go wrong
- This is a completed Phase 4 trial with 202 participants, so results are already in. However, late presenters may have more advanced disease, and individual responses can vary. The study is open-label, which may introduce bias.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Liaoning Dalian Public Health Clinical Center
Dalian, Liaoning, China
-
Lanzhou Feike Hospital
Lanzhou, Guansu, China
-
The Guangxi Zhuang Autonomous Region Longtan Hospital
Liuzhou, Guangxi, 545005, China
-
The Second Hospital of Nanjing
Najing, Jiangsu, 210003, China
-
Tianjin Second People's Hospital
Tianjin, 300192, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single HIV pill tame the epidemic in africa?
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
- Could a shot replace daily HIV pills? new trial tests injectable combo